
ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call Transcript

I initiate ProQR Therapeutics N.V. with a Buy rating, driven by strong initial human proof-of-concept for its Axiomer RNA editing platform. The company's AX-0810 achieved 8-fold serum bile acid increa